Background:
Population based registries under National Cancer Registry Program indicate that 50-60% of all cancers among Indian females, are related to breast and genital organs, with adverse influence on their productive role. Over 70% report in advanced stages and have high mortality rates.
Aim:
To identify leading sites of neoplasm in females and detailed analysis of gynecological malignancies, in all age groups and to compare results with national and global data, with application of knowledge in early detection as emphasized by India’s National Cancer Control Programme.
Methods:
Systematic extraction of demographic and clinical details from hospital cancer registry between January 2011 to December 2013 was conducted to identify children, adolescents, young adults, and elder females diagnosed with various malignancies. Thereafter observation was analyzed system-wise and year-wise to determine trends.
Results:
Female neoplasm constituted 13,412 (44.53%) of 30,120 total new patients registered with DSCI during three years, in males, females and children categories. Benign female neoplasms were 3420(25.15%). Of 9992 female malignancies registered, mammary glands were leading site 2513 (25.15%), followed by hepato- biliary and gastrointestinal system 2229 (22.31%), gynaecological malignancies 2200 (22.02%) , oro-facial-pharyngial cancers 698 (6.99%) and hematological and lymphoproliferative malignancies 651(6.51%).
Leading ten organs constituting 71.6% of female malignancies were breast 2513(25.15%), Uterine cervix 1290 (12.91%), Gall Bladder 1224((12.25%), Ovary 620(6.21%), Bronchoalveolar 351(3.51%), Esophagus 262 (2.62%), Tongue 256(2.56%), Brain 232(2.32%), Hepatobiliary 221(2.21%), and Uterine corpus 186(1.86%).
Of gynecological malignancies, uterine cervix was commonest followed by ovarian and uterine cancers.
Year wise evaluation showed trends of common female malignancies to be similar every year.
Conclusions:
Analysis of cancer registries at DSCI is a guide to trends of common female malignancies, so as to target clinical programs in screening, early detection, and treatment aptly, to reduce advanced stages reporting.